Accelerating Kinase Drug Discovery with Validated Kinase Activity Assay Kits

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer. Kinase drug discovery programs rely on the precise characterization and screening of potent kinase inhibitors. A clinically proven and validated assay platform is essential for integrating into these active discovery and development pipelines. Traditional methods for measuring kinase activity, such as those using radioisotopes or simple binding studies, can be challenging, unsafe, and often fail to correlate binding data with functional enzymatic activity strongly. Furthermore, due to the presence of conserved active sites and high structural homology among kinases, developing selective kinase inhibitors is a complex process that requires validation at every step.